Skip to main content

Advertisement

SpringerLink
Log in

Asynchronous leptomeningeal carcinomatosis from pancreatic cancer: a case report and review of the literature

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Central nervous system (CNS) metastases from pancreatic cancer are an exceedingly rare occurrence and have been predominantly described as focal lesions within the brain parenchyma. Even fewer reports exist of tumor spread to the leptomeninges, and most cases are discovered at autopsy. No report of leptomeningeal carcinomatosis without brain parenchymal involvement has been described to date. We describe a 72-year-old female diagnosed with inoperable, stage IV pancreatic cancer. She was treated with combination chemotherapy comprising Reolysin (reovirus serotype-3 Dearing strain), carboplatin, and paclitaxel. After 4 months of treatment, her tumor had decreased in size by 55 %, and CA19-9 levels had dropped 25-fold. However, 7 months after her initial cancer diagnosis, she presented with clinical symptoms and radiographic findings consistent with leptomeningeal carcinomatosis. Lumbar puncture did not reveal malignant cells in the cerebrospinal fluid (CSF), and biopsy was requested for tissue diagnosis. This confirmed pancreatic leptomeningeal carcinomatosis. Our case report demonstrates that leptomeningeal spread from pancreatic tumors may develop independent of focal brain parenchymal involvement and in the setting of controlled systemic disease. Furthermore, the present study describes the first case of CNS progression in the setting of systemic response to Reolysin therapy, suggesting this newly developing treatment may not prevent neurological spread of disease. If repeat cytology of CSF fails to detect malignant cells, biopsy should be pursued for definitive diagnosis. Surgery may also concurrently provide an opportunity to place an intraventricular catheter for delivery of intrathecal chemotherapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol. 1990;9:225–9.

    Article  PubMed  CAS  Google Scholar 

  2. Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin. 2003;21:25–66.

    Article  PubMed  Google Scholar 

  3. de Azevedo CRAS, Cruz MRS, Chinen LTD, et al. Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neurooncol. 2011;104:565–72.

    Article  PubMed  Google Scholar 

  4. Rudnicka H, Niwińska A, Gruszfeld A, et al. Diagnosis and treatment of carcinoid meningitis: a challenge to the neurologist and oncologist. Neurol Neurochir Pol. 2003;37:811–24.

    PubMed  Google Scholar 

  5. Strong JE, Coffey MC, Tang D, et al. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998;17:3351–62.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Norman KL, Hirasawa K, Yang AD, et al. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA. 2004;101:11099–104.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  7. Coffey MC, Strong JE, Forsyth PA, et al. Reovirus therapy of tumors with activated Ras pathway. Science. 1998;282:1332–4.

    Article  PubMed  CAS  Google Scholar 

  8. Shmulevitz M, Marcato P, Lee PW. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene. 2005;24:7720–8.

    Article  PubMed  CAS  Google Scholar 

  9. Galanis E, Markovic SN, Suman VJ, et al. Phase II trial of intravenous administration of Reolysin((R)) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther. 2012;20:1998–2003.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Morris DG, Feng X, DiFrancesco LM, et al. REO-001: a phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin(R)) in patients with advanced solid tumors. Invest New Drugs. 2013;31:696–706.

    Article  PubMed  CAS  Google Scholar 

  11. Lolkema MP, Arkenau HT, Harrington K, et al. A phase I study of the combination of intravenous reovirus type 3 dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res. 2011;17:581–8.

    Article  PubMed  CAS  Google Scholar 

  12. Comins C, Spicer J, Protheroe A, et al. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res. 2010;16:5564–72.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Harrington KJ, Karapanagiotou EM, Roulstone V, et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res. 2010;16:3067–77.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Vidal L, Pandha HS, Yap TA, et al. A phase I study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer. Clin Cancer Res. 2008;14:7127–37.

    Article  PubMed  CAS  Google Scholar 

  15. Karapanagiotou EM, Roulstone V, Twigger K, et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res. 2012;18:2080–9.

    Article  PubMed  CAS  Google Scholar 

  16. Wolfgang G, Marcus D, Ulrike S. LC: clinical syndrome in different primaries. J Neurooncol. 1998;38:103–10.

    Article  PubMed  CAS  Google Scholar 

  17. Chamberlain MC. Neoplastic meningitis: a guide to diagnosis and treatment. Curr Opin Neurol. 2000;13:641–8.

    Article  PubMed  CAS  Google Scholar 

  18. Martins SJ, Azevedo CR, Chinen LT, et al. Meningeal carcinomatosis in solid tumors. Arq Neuropsiquiatr. 2011;69:973–80.

    Article  PubMed  Google Scholar 

  19. Mao C, Domenico DR, Kim K, et al. Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg. 1995;130:125–34.

    Article  PubMed  CAS  Google Scholar 

  20. Kamisawa T, Isawa T, Koike M, et al. Hematogenous metastases of pancreatic ductal carcinoma. Pancreas. 1995;11:345–9.

    Article  PubMed  CAS  Google Scholar 

  21. Matsuno S, Kato S, Kobari M, et al. Clinicopathological study on hematogenous metastasis of pancreatic cancer. Jpn J Surg. 1986;16:406–11.

    Article  PubMed  CAS  Google Scholar 

  22. Gil Z, Cavel O, Kelly K, et al. Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. J Natl Cancer Inst. 2010;102:107–18.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. Stopczynski RE, Normolle DP, Hartman DJ, et al. Neuroplastic changes occur early in the development of pancreatic ductal adenocarcinoma. Cancer Res. 2014;74:1718–27.

    Article  PubMed  CAS  Google Scholar 

  24. Lemke J, Scheele J, Kapapa T, et al. Brain metastasis in pancreatic cancer. Int J Mol Sci. 2013;14:4163–73.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Bartsch R, Berghoff AS, Preusser M. Optimal management of brain metastases from breast cancer. Issues and considerations. CNS Drugs. 2013;27:121–34.

    Article  PubMed  CAS  Google Scholar 

  26. Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom? Blood Rev. 2012;26:97–106.

    Article  PubMed  Google Scholar 

  27. Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist. 2003;8:398–410.

    Article  PubMed  Google Scholar 

  28. Glantz MJ, Van Horn A, Fisher R, et al. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer. 2010;116:1947–52.

    Article  PubMed  Google Scholar 

  29. Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology. 1994;44:1463–9.

    Article  PubMed  CAS  Google Scholar 

  30. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5:3394–402.

    PubMed  CAS  Google Scholar 

  31. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110–6.

    PubMed  CAS  Google Scholar 

  32. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol. 1993;11:561–9.

    PubMed  CAS  Google Scholar 

  33. Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987;5:1655–62.

    PubMed  CAS  Google Scholar 

  34. Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int. 2013;4:S265–88.

    PubMed  PubMed Central  Google Scholar 

  35. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol. 1978;19:579–92.

    PubMed  CAS  Google Scholar 

  36. Shapiro WR, Posner JB, Ushio Y, et al. Treatment of meningeal neoplasms. Cancer Treat Rep. 1977;61:733–43.

    PubMed  CAS  Google Scholar 

  37. Cante D, Franco P, Sciacero P, et al. Leptomeningeal metastasis from prostate cancer. Tumori. 2013;99:6e–10e.

    PubMed  Google Scholar 

  38. Lahiri RP, Burnand KM, Bandi A, et al. Colorectal cancer presenting with dysarthria and ataxia: a case of isolated leptomeningeal metastasis. Ann R Coll Surg Engl. 2011;93:e133–5.

    Article  PubMed  CAS  Google Scholar 

  39. Miller E, Dy I, Herzog T. Leptomeningeal carcinomatosis from ovarian cancer. Med Oncol. 2012;29:2010–5.

    Article  PubMed  CAS  Google Scholar 

  40. Oh SY, Lee SJ, Lee J, et al. Gastric leptomeningeal carcinomatosis: multi-center retrospective analysis of 54 cases. World J Gastroenterol. 2009;15:5086–90.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Onesti E, Fabi A, Mingoia M, et al. Leptomeningeal carcinomatosis in aggressive germ non-seminoma testicular tumor: a case report and review of literature. Clin Neurol Neurosurg. 2012;114:1081–5.

    Article  PubMed  Google Scholar 

  42. Kashiwagi S, Asano Y, Watanabe M, et al. Four cases of meningeal metastasis originating from breast cancer. Gan To Kagaku Ryoho. 2012;39:1917–9.

    PubMed  Google Scholar 

  43. Stemmler HJ, Mengele K, Schmitt M, et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs. 2008;19:832–6.

    Article  PubMed  CAS  Google Scholar 

  44. Gordon AN, Kavanagh JJ Jr, Wharton JT, et al. Successful treatment of leptomeningeal relapse of epithelial ovarian cancer. Gynecol Oncol. 1984;18:119–24.

    Article  PubMed  CAS  Google Scholar 

  45. Ferreira Filho AF, Cardoso F, Di Leo A, et al. Carcinomatous meningitis as a clinical manifestation of pancreatic carcinoma. Ann Oncol. 2001;12:1757–9.

    Article  PubMed  CAS  Google Scholar 

  46. Grira MT, Ben Jemaa HM, Lammouchi TM, et al. Meningitis revealing pancreatic carcinoma. Neurosciences (Riyadh). 2007;12:256–8.

    Google Scholar 

  47. Minchom A, Chan S, Melia W, et al. An unusual case of pancreatic cancer with leptomeningeal infiltration. J Gastrointest Cancer. 2010;41:107–9.

    Article  PubMed  Google Scholar 

  48. Tyler KL, Barton ES, Ibach ML, et al. Isolation and molecular characterization of a novel type 3 reovirus from a child with meningitis. J Infect Dis. 2004;189:1664–75.

    Article  PubMed  CAS  Google Scholar 

  49. Kicielinski KP, Chiocca EA, Yu JS, et al. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther. 2014;22:1056–62.

    Article  PubMed  CAS  Google Scholar 

  50. Forsyth P, Roldan G, George D, et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther. 2008;16:627–32.

    Article  PubMed  CAS  Google Scholar 

  51. Alloussi SH, Alkassar M, Urbschat S, et al. All reovirus subtypes show oncolytic potential in primary cells of human high-grade glioma. Oncol Rep. 2011;26:645–9.

    PubMed  CAS  Google Scholar 

  52. Wilcox ME, Yang W, Senger D, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst. 2001;93:903–12.

    Article  PubMed  CAS  Google Scholar 

  53. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999;25:103–19.

    Article  PubMed  CAS  Google Scholar 

  54. Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82:733–9.

    Article  PubMed  CAS  Google Scholar 

  55. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293:161–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosures

Conflict of Interest:

Christopher S. Hong, Habibe Kurt, and J. Bradley Elder declare no conflict of interest.

Human/Animal Rights:

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008(5).

Informed Consent:

Informed consent was obtained from all patients for being included in the study.

Author information

Authors and Affiliations

  1. Department of Neurological Surgery, The Ohio State University Wexner Medical Center, 410 W 10th Ave., Doan Hall, N1052, Columbus, OH, 43210, USA

    Christopher S. Hong & J. Bradley Elder

  2. Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA

    Habibe Kurt

Authors
  1. Christopher S. Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Habibe Kurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Bradley Elder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Bradley Elder.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hong, C.S., Kurt, H. & Elder, J.B. Asynchronous leptomeningeal carcinomatosis from pancreatic cancer: a case report and review of the literature. Clin J Gastroenterol 7, 434–440 (2014). https://doi.org/10.1007/s12328-014-0518-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-014-0518-y

Keywords

Search

Navigation